Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 9, 2025, serves as a transaction notification for the month of December 2025. The document discloses a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share sale transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Volume | 6,000 shares |
| Price per Share | £18.2870 |
| Transaction Date | December 5, 2025 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records a reduction in the shareholding of a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a mandatory disclosure of an insider transaction.
Key Facts for Investor Verification
- Executive Involved: Sally Jackson, SVP, Global Communications & CEO Office.
- Transaction Nature: Initial notification of a sale of 6,000 ordinary shares.
- Market Price: The shares were sold at £18.2870 each on December 5, 2025.
- Regulatory Context: This is a standard insider trading disclosure required under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.